From Bench to Bedside: Accelerating from Preclinical to POC with a Truly Integrated development partner

Location : Atelier des Saveurs

This seminar provides a focused look at the transition of drug candidates from preclinical stages into first‑in‑human (FIH) and early patient studies. Presentations explore how predictive modelling, solubility assessment, and formulation screening support safer, smarter progression into clinical development.

Participants will also gain insight into formulation selection and integrated drug product supply strategies, including how Translational Pharmaceutics® and adaptive manufacturing can accelerate timelines and enhance flexibility from FIH to proof‑of‑concept (PoC).

The event includes interactive Q&A with Quotient Sciences experts, offering practical guidance and real‑world case studies to help optimise molecule readiness, streamline early‑phase operations, and improve clinical outcomes.

Learning objectives:

• Key considerations when moving from preclinical to FIH.
• How formulation strategies impact flexibility and patient outcomes.
• Understanding how Quotient’s integrated services and Translational Pharmaceutics support efficient development and patient supply.

To register click here !